Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
NSPR's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: No Debt )
NSPR' s 10-Year Cash to Debt Range
Min: 0.34   Max: No Debt
Current: No Debt

Equity to Asset 0.74
NSPR's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 0.74 )
NSPR' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.78
Current: 0.74

-0.35
0.78
F-Score: 4
Z-Score: 0.42
M-Score: -6.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -228.66
NSPR's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -228.66 )
NSPR' s 10-Year Operating margin (%) Range
Min: -228.66   Max: -228.66
Current: -228.66

Net-margin (%) -244.25
NSPR's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -244.25 )
NSPR' s 10-Year Net-margin (%) Range
Min: -244.25   Max: -244.25
Current: -244.25

ROE (%) -217.13
NSPR's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -217.13 )
NSPR' s 10-Year ROE (%) Range
Min: -217.13   Max: -200
Current: -217.13

-217.13
-200
ROA (%) -140.13
NSPR's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -140.13 )
NSPR' s 10-Year ROA (%) Range
Min: -400   Max: -80
Current: -140.13

-400
-80
ROC (Joel Greenblatt) (%) -758.93
NSPR's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -758.93 )
NSPR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -758.93   Max: -758.93
Current: -758.93

» NSPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NSPR



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about InspireMD Inc

InspireMD Reports 4 Significant Insider Buys
InspireMD (NSPR) reported four large insider buys last week. These came as the company announced the closing of an underwritten public offering of 12.5 million shares of its common stock at a price of $2.00 per share. The company received net proceeds of approximately $22.6 million from this public offering. Read more...

Ratios

vs
industry
vs
history
P/B 6.50
NSPR's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 6.50 )
NSPR' s 10-Year P/B Range
Min: 4.35   Max: 420
Current: 6.5

4.35
420
P/S 10.50
NSPR's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 10.50 )
NSPR' s 10-Year P/S Range
Min: 8.08   Max: 54
Current: 10.5

8.08
54
EV-to-EBIT 9.30
NSPR's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 9.30 )
NSPR' s 10-Year EV-to-EBIT Range
Min: 1.8   Max: 3.9
Current: 9.3

1.8
3.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.30
NSPR's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 12.30 )
NSPR' s 10-Year Price/Net Cash Range
Min: 7.37   Max: 109
Current: 12.3

7.37
109
Price/Net Current Asset Value 9.10
NSPR's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 9.10 )
NSPR' s 10-Year Price/Net Current Asset Value Range
Min: 5.97   Max: 51.43
Current: 9.1

5.97
51.43
Price/Tangible Book 6.50
NSPR's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 6.50 )
NSPR' s 10-Year Price/Tangible Book Range
Min: 4.6   Max: 390
Current: 6.5

4.6
390
Price/Median PS Value 0.70
NSPR's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 0.70 )
NSPR' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 3.47
Current: 0.7

0.62
3.47

Business Description

Industry: »
Compare: » details
InspireMD, Inc. was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. to engage in the acquisition, exploration and development of natural resource properties. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from 'Saguaro Resources, Inc.' to 'InspireMD, Inc.' It is an innovative medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience major adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.
» More Articles for AMEX:NSPR

Headlines

Articles On GuruFocus.com
InspireMD Reports 4 Significant Insider Buys Apr 19 2013 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide